L. Zalkow

发表

A multiwell assay for inhibitors of phosphatidylinositol-3-kinase and the identification of natural product inhibitors.

G. Powis, R. Abraham, M. Berggren, 1994, Anticancer research.

Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase.

J. Dodge, G. Powis, R. Abraham, 1994, Cancer research.

Advances with phospholipid signalling as a target for anticancer drug development.

G. Powis, R. Abraham, M. Berggren, 1995, Acta biochimica Polonica.

Novel quinone antiproliferative inhibitors of phosphatidylinositol-3-kinase.

G. Powis, R. Abraham, M. Berggren, 1995, Anti-Cancer Drug Design.

Syntheses and biological activities of a novel group of steroidal derived inhibitors for human Cdc25A protein phosphatase.

G. Powis, R. Abraham, J. Cogswell, 2001, Journal of medicinal chemistry.

A multisample assay for inhibitors of phosphatidylinositol phospholipase C: identification of naturally occurring peptide inhibitors with antiproliferative activity.

G. Powis, R. Abraham, C. Ashendel, 1994, Anti-cancer drug design.

3Beta-hydroxy-6-aza-cholestane and related analogues as phosphatidylinositol specific phospholipase C (PI-PLC) inhibitors with antitumor activity.

Y. Li, M. Kunkel, G. Powis, 2000, Bioorganic & medicinal chemistry.

Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues

G. Powis, R. Abraham, A. Gallegos, 1997, Cancer Chemotherapy and Pharmacology.

Inhibition of glycosylphosphatidylinositol (GPI) phospholipase D by suramin-like compounds.

D. Rifkin, G. Powis, L. Zalkow, 1996, Anticancer research.